

DIN EN ISO 5840-3:2021-05 (E)

Cardiovascular implants - Cardiac valve prostheses - Part 3: Heart valve substitutes implanted by transcatheter techniques (ISO 5840-3:2021)

Contents		Page
European foreword		4
Foreword		5
Introduction		6
1	Scope	7
2	Normative references	7
3	Terms and definitions	7
4	Abbreviations	10
5	Fundamental requirements	11
6	Device description	11
6.1	General	11
6.2	Intended use	12
6.3	Design inputs	12
6.3.1	Operational specifications	12
6.3.2	Performance specifications	12
6.3.3	Implant procedure	13
6.3.4	Packaging, labelling and sterilization	13
6.4	Design outputs	13
6.5	Design transfer (manufacturing verification/validation)	13
6.6	Risk management	13
7	Design verification and validation	14
7.1	General requirements	14
7.2	In vitro assessment	14
7.2.1	General	14
7.2.2	Test conditions, sample selection and reporting requirements	14
7.2.3	Material property assessment	14
7.2.4	Hydrodynamic performance assessment	14
7.2.5	Structural performance assessment	16
7.2.6	Design- or procedure-specific testing	16
7.2.7	Device MRI compatibility	18
7.2.8	Simulated use	18
7.2.9	Human factors and usability assessment	18
7.2.10	Implant thrombogenic and haemolytic potential assessment	18
7.3	Preclinical in vivo evaluation	18
7.3.1	General	18
7.3.2	Overall requirements	19
7.3.3	Methods	20
7.3.4	Test report	21
7.4	Clinical investigations	22
7.4.1	General	22
7.4.2	Study considerations	23
7.4.3	Study endpoints	24
7.4.4	Ethical considerations	25

7.4.5	Pivotal studies: Distribution of subjects and investigators	25
7.4.6	Statistical considerations including sample size and duration	26
7.4.7	Patient selection criteria	28
7.4.8	Valve thrombosis prevention	28
7.4.9	Clinical data requirements	29
Annex A (informative)	Description of the transcatheter heart valve system	34
Annex B (informative)	Transcatheter heart valve substitute hazard analysis example	36
Annex C (informative)	Guidelines for verification of hydrodynamic performance-- Pulsatile flow testing	38
Annex D (normative)	Requirements for delivery system design and evaluation	46
Annex E (informative)	Examples of design specific testing	48
Annex F (informative)	Preclinical in vivo evaluation	50
Annex G (normative)	Adverse event classification during clinical investigation	53
Annex H (informative)	Multimodality imaging of TAVI and TMVI pre, peri and post- implantation assessments -- Examples	59
Bibliography	62